Appili Therapeutics Inc
Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a liquid oral taste-masked reformulation of the antibiotic metronidazole to treat anaerobic bacterial, protozoal, and parasitic infections; ATI-1801, a novel topical formulation of paro… Read more
Market Cap & Net Worth: Appili Therapeutics Inc (APLIF)
Appili Therapeutics Inc (PINK:APLIF) has a market capitalization of $2.43 Million ($2.43 Million) as of March 19, 2026. Listed on the PINK stock exchange, this USA-based company holds position #34673 globally and #11317 in its home market, demonstrating a -28.83% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Appili Therapeutics Inc's stock price $0.02 by its total outstanding shares 121266120 (121.27 Million).
Appili Therapeutics Inc Market Cap History: 2020 to 2025
Appili Therapeutics Inc's market capitalization history from 2020 to 2025. Data shows change from $114.43 Million to $2.43 Million (-56.85% CAGR).
Appili Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Appili Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
24.15x
Appili Therapeutics Inc's market cap is 24.15 times its annual revenue
1740.90x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $114.43 Million | $199.11K | -$4.33 Million | 574.70x | N/A |
| 2021 | $10.91 Million | $1.39 Million | -$14.33 Million | 7.85x | N/A |
| 2022 | $4.37 Million | $1.39 Million | -$25.12 Million | 3.14x | N/A |
| 2023 | $3.27 Million | $334.18K | -$9.24 Million | 9.80x | N/A |
| 2024 | $3.15 Million | $827.41K | -$3.78 Million | 3.81x | N/A |
| 2025 | $2.43 Million | $100.44K | -$2.62 Million | 24.15x | N/A |
Competitor Companies of APLIF by Market Capitalization
Companies near Appili Therapeutics Inc in the global market cap rankings as of March 19, 2026.
Key companies related to Appili Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #165 globally with a market cap of $114.33 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #285 globally with a market cap of $73.32 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #340 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #497 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #165 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $114.33 Billion | $451.59 |
| #285 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $73.32 Billion | $744.12 |
| #340 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #497 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Appili Therapeutics Inc Historical Marketcap From 2020 to 2025
Between 2020 and today, Appili Therapeutics Inc's market cap moved from $114.43 Million to $ 2.43 Million, with a yearly change of -56.85%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $2.43 Million | -23.08% |
| 2024 | $3.15 Million | -3.70% |
| 2023 | $3.27 Million | -25.00% |
| 2022 | $4.37 Million | -60.00% |
| 2021 | $10.91 Million | -90.46% |
| 2020 | $114.43 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 19th, 2026 the market cap of Appili Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.43 Million USD |
| MoneyControl | $2.43 Million USD |
| MarketWatch | $2.43 Million USD |
| marketcap.company | $2.43 Million USD |
| Reuters | $2.43 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.